A green light from the US regulator for aducanumab is a huge boost for Biogen, but not everyone will be celebrating.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Lilly and Roche bask in the reflected glow of aducanumab's benign briefing documents.
Oncology dominates upcoming catalysts, while results elsewhere are expected in Alzheimer’s, psoriasis and diabetes.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Clinical data near for Alzheimer’s antibodies from Roche and Lilly, while Cortexyme and Biohaven test small molecules.
A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.